NBRV Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 jul 2023 @ 22:00):

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections...

Stats
Dagens volum	706 536
Gjennomsnittsvolum	13 843.00
Markedsverdi	4.55M
EPS	$-4.50 ( 2023-08-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0722
ATR14	$0.181 (28.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-06	Hogan H Michael Iii	Buy	0
2023-06-30	Maggio David	Buy	0
2023-01-29	Gelone Steven P.	Sell	140	Ordinary Shares
2023-01-29	Schroeder Theodore R	Sell	431	Ordinary Shares
2023-01-06	Gelone Steven P.	Sell	5	Ordinary Shares

INSIDER POWER
20.49
Last 98 transactions
Buy: 1 927 900 \| Sell: 612 376

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: 0.60 (weak)

Signal:(34.114) Neutral

Nabriva Therapeutics PLC Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Nabriva Therapeutics PLC Korrelasjon - Valuta/Råvare

-0.66
( moderate negative )

-0.64
( weak negative )

0.54
( weak )

-0.55
( weak negative )

0.59
( weak )

Nabriva Therapeutics PLC Økonomi

Annual	2022
Omsetning:	$35.67M
Bruttogevinst:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2022
Omsetning:	$35.67M
Bruttogevinst:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2021
Omsetning:	$28.90M
Bruttogevinst:	$15.75M (54.50 %)
EPS:	$-96.24

FY	2020
Omsetning:	$2.86M
Bruttogevinst:	$2.10M (73.25 %)
EPS:	$-135.23

Financial Reports:

No articles found.

Nabriva Therapeutics PLC

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.